Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease

Inclusion Criteria: * Chronic kidney disease patients aged 18 to 80 years * Chronic kidney disease stage 3 (defined as a glomerular filtration rate of 30-60 ml/min/1.73m2) * Office blood pressure controlled to less than 140/90 mmHg for 12 months before entry into the study * Total cholesterol less than 5.5 mmol/l Exclusion Criteria: * Existing or previous treatment within 1 year with a phosphate binder or vitamin D analogue * Uncontrolled hyperphosphataemia (serum phosphate \>1.8 mmol/l) * Uncontrolled secondary hyperparathyroidism (PTH \>80 pg/ml) * Diabetes mellitus * Pregnancy * Moderate-severe cardiac valvular disease